Bentley Systems Releases Open-Source Library: iModel.js
17.10.2018 11:58:00 EEST | Business Wire | Press release
Bentley Systems, Incorporated, the leading global provider of comprehensive software solutions for advancing the design, construction, and operations of infrastructure, today announced the initial release of its iModel.js library, an open-source initiative to improve the accessibility, for both visualization and analytical visibility, of infrastructure digital twins. iModel.js can be used by developers and IT professionals to quickly and easily create immersive applications that connect their infrastructure digital twins with the rest of their digital world. iModel.js is the cornerstone of Bentley’s just-announced iTwin™ Services that combine iModelHub, reality modeling, and web-enabling software technologies within a Connected Data Environment (CDE) for infrastructure engineering.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181017005008/en/
Bentley Systems Releases Open-Source Library: iModel.js.(Photo: Business Wire)
Bentley’s iModels have become a de facto standard for visibility into digital engineering models. iModelHub manages an iModel as a distributed database with an intrinsic ledger of changes—enabling alignment, accountability, and accessibility of its digital components—to form the backbone of an infrastructure digital twin.
The iModel.js library is a comprehensive collection of JavaScript packages that build on the most open, popular, and flexible standards for modern cloud and web development. It is written in TypeScript, and leverages open technologies including SQLite, Node.js, NPM, WebGL, Electron, Docker, Kubernetes, and of course HTML5 and CSS. The same codebase can produce cloud services and web, mobile, and desktop applications. The source code is hosted on GitHub and is distributed under the MIT license.
With iModel.js, it is simple to create a web-based experience that shows interactive “nD” views (1D, 2D, 3D, 4D, etc.) of iModels that are assembled and synchronized from BIM files and other digital engineering models, and from data created directly with iModel.js. Those same views can also include digital (reality) context, real-time sensor data, and other data from enterprise sources and analytics. Since the iModel is synchronized by iModelHub, it always reflects the most recent updates from all project participants, who are thus able to visualize and analyze changes between points in time or between versions. Importantly, only users and applications authorized by the iModel owner, through iModelHub, are granted access through iModel.js.
Johan Palm, program manager – Digital Project Delivery at Hatch, said, “iModel.js gives Hatch the ability to implement a stakeholder engagement technology that extends the iModelHub visionary technology. We can expose complex project information to a level that is accessible, consumable, and extendable via the cloud and in context to the 3D model. Most importantly we can do so in a manner that embraces change as the project progresses. iModel.js aligns with Hatch’s internal development strategies as it is built on modern, highly portable web technology. Bentley is a key software technology partner on Hatch projects globally where our main objective is to provide a positive impact to our client’s assets and operations.”
Cai Chengguo, chair and general manager, Shenzhen Expressway Consulting Group, said, “The digital twin powered by iModelHub is efficiently improving project management, substantially reducing the waste of resources caused by site problems and will achieve digital handover after completion of the project for visual operations and maintenance.”
Keith Bentley, Bentley Systems’ founder and CTO, said, “We firmly believe that iModel.js, and of course the foundation upon which it is built, is the most open, productive, intuitive, and powerful development environment for capital projects and infrastructure assets, ever. We’re excited to work with user organizations, strategic partners, and third-party developers to build an open ecosystem around iModels to tap the vast potential of infrastructure digital twins. With iModel.js, the well-refined techniques of mainstream cloud and web development can leverage the physical and virtual reality in digital twins with near-zero impedance. By open-sourcing the libraries we use to create our iTwin™ cloud services, we expect to foster a substantial and vibrant ecosystem of innovation.”
More about iModel.js: iModeljs.org.
More about iModels and iModelHub: iModelHub.com.
About Bentley Systems
Bentley Systems is the leading global
provider of software solutions to engineers, architects, geospatial
professionals, constructors, and owner-operators for the design,
construction, and operations of infrastructure. Bentley’s MicroStation-based
engineering and BIM applications, and its digital twin cloud services,
advance the project delivery (ProjectWise) and the asset
performance (AssetWise) of transportation and other public works,
utilities, industrial and resources plants, and commercial and
institutional facilities.
Bentley Systems employs more than 3,500 colleagues, generates annual
revenues of $700 million in 170 countries, and has invested more than $1
billion in research, development, and acquisitions since 2012. From
inception in 1984, the company has remained majority-owned by its five
founding Bentley brothers. Bentley shares transact by invitation on the
NASDAQ Private Market; strategic partner Siemens AG has accumulated a
non-voting minority stake
www.bentley.com
Bentley, the Bentley logo, AssetWise, Connected Data Environment, iTwin, MicroStation, and ProjectWise are either registered or unregistered trademarks or service marks of Bentley Systems, Incorporated or one of its direct or indirect wholly owned subsidiaries. All other brands and product names are trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181017005008/en/
Contact information
Press:
Bentley Systems
Jennifer Maguire
+1 610 458 2695
jennifer.maguire@bentley.com
Follow
us on Twitter: @BentleySystems
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
